The company that makes Botox is the subject of the latest biopharma mega-deal.
Chicago-based AbbVie said Tuesday it would acquire Ireland-headquartered Allergan for $63 billion, or $78.45 per share, equal to the former’s Monday closing price. The companies said the deal would provide immediate scale and profitability for AbbVie while allowing the company to diversify into new therapeutic areas like aesthetics.
{iframe}https://medcitynews.com/2019/06/abbvie-to-buy-allergan-for-63b/?rf=1&utm_campaign=MCN%20Daily%20Top%20Stories&utm_source=hs_email&utm_medium=email&utm_content=74066356&_hsenc=p2ANqtz-_IaM0OhnDf5mdW5EvIRslV_1cGDLnA3u3KHQIgrvtoRrCnUkMGl1pBZltWGGtimoIL9Mt14OFX6mri_N8rglegWcBIdg&_hsmi=74066356{/iframe}